Spectral Medical (TSE:EDT)
TSX:EDT
Top Page
Spectral Medical
(TSX:EDT)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$1.50
▲(7.14% Upside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by very weak financial performance (deep losses, persistent cash burn, and a highly strained balance sheet with negative equity and rising debt). Technicals are a notable offset with price above major moving averages and positive MACD, but valuation remains challenged due to negative earnings and no dividend yield provided.
Positive Factors
Focused critical-care product portfolio
Spectral Medical’s PMX device and companion diagnostics target a high‑severity critical care indication (sepsis/septic shock). This focused clinical niche creates durable demand, potential for specialized reimbursement, and a clear go‑to‑market value proposition that can support steady long‑term adoption if clinical benefits persist.
Negative Factors
Persistent heavy cash burn
Sustained negative operating and free cash flow (~-$10.2M TTM) signals ongoing funding needs. Over multiple quarters this erodes liquidity, forces dilution or debt financing, and restricts the company’s ability to invest in commercialization and trials—threatening long‑term execution without reliable financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused critical-care product portfolio
Spectral Medical’s PMX device and companion diagnostics target a high‑severity critical care indication (sepsis/septic shock). This focused clinical niche creates durable demand, potential for specialized reimbursement, and a clear go‑to‑market value proposition that can support steady long‑term adoption if clinical benefits persist.
Read all positive factors
Spectral Medical (EDT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$409.59M
Dividend YieldN/A
Average Volume (3M)78.93K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth34.85%
EPS Growth-62.50%
CountryCA
Employees29
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding292,562,930
10 Day Avg. Volume98,063
30 Day Avg. Volume78,934
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-5.93
Price to Sales (P/S)169.36
P/FCF Ratio-35.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.47Price Target Upside147.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$4.99M
Spectral Medical Business Overview & Revenue Model
Company Description
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitr...
How the Company Makes Money
null...
Spectral Medical Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.44M | 2.29M | 1.60M | 1.67M | 2.00M |
| Gross Profit | -5.16M | 1.02M | 662.00K | 983.00K | 1.16M |
| EBITDA | -11.44M | -11.97M | -13.96M | -7.18M | -6.38M |
| Net Income | -47.69M | -15.40M | -15.66M | -11.28M | -8.79M |
Balance Sheet | |||||
| Total Assets | 6.10M | 5.32M | 5.21M | 12.00M | 11.55M |
| Cash, Cash Equivalents and Short-Term Investments | 4.07M | 2.99M | 2.95M | 8.41M | 8.89M |
| Total Debt | 21.09M | 14.93M | 8.56M | 7.57M | 582.00K |
| Total Liabilities | 75.82M | 32.87M | 21.76M | 14.55M | 7.47M |
| Stockholders Equity | -69.72M | -27.55M | -16.55M | -2.55M | 4.08M |
Cash Flow | |||||
| Free Cash Flow | -11.63M | -8.85M | -10.91M | -9.93M | -9.18M |
| Operating Cash Flow | -11.63M | -8.82M | -10.72M | -9.90M | -8.70M |
| Investing Cash Flow | -195.00K | -27.00K | -185.00K | -33.00K | -325.00K |
| Financing Cash Flow | 12.91M | 8.88M | 5.44M | 9.46M | 12.16M |
Spectral Medical Technical Analysis
Positive
1.40
Price Trends
1.33
Positive
1.34
Positive
1.27
Positive
Market Momentum
0.02
Negative
61.93
Neutral
74.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EDT, the sentiment is Positive. The current price of 1.4 is above the 20-day moving average (MA) of 1.33, above the 50-day MA of 1.33, and above the 200-day MA of 1.27, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.93 is Neutral, neither overbought nor oversold. The STOCH value of 74.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EDT.
Spectral Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | C$463.66M | 10.05 | 24.23% | ― | 94.28% | 5.23% | |
55 Neutral | C$323.76M | -198.83 | -3.55% | ― | 33.27% | 86.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$409.59M | -37.02 | ― | ― | 34.85% | -62.50% | |
48 Neutral | C$60.95M | -32.47 | ― | ― | -21.89% | 26.36% | |
46 Neutral | C$300.15M | -5.47 | -85.73% | ― | 72.03% | -1.47% | |
41 Neutral | C$35.46M | -21.43 | -434.25% | ― | ― | 10.97% |
* Healthcare Sector Average
TSE:EDT
Spectral Medical
1.40
0.63
81.82%
TSE:CPH
Cipher Pharmaceuticals
18.34
5.59
43.84%
TSE:BUX
BioMark Diagnostics
0.58
0.31
114.81%
TSE:KSI
kneat.com
3.38
-2.86
-45.83%
TSE:PRN
Profound Medical
8.27
0.06
0.73%
TSE:SONA
Sona Nanotech Inc
0.31
0.02
6.90%
Spectral Medical Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related AnnouncementsRegulatory Filings and Compliance
Spectral Medical Advances PMX Toward FDA Submission After Positive Tigris Results
Positive
Mar 26, 2026
Spectral Medical reported its fourth quarter and full-year 2025 results alongside a corporate update that underscored major clinical and regulatory progress for its PMX therapy in endotoxic septic shock. The company highlighted completion of enrol...
Business Operations and StrategyProduct-Related Announcements
Spectral Medical’s Tigris Trial Shows Survival Benefit in Endotoxic Septic Shock
Positive
Mar 24, 2026
Spectral Medical and Vantive reported that full results from the Phase 3 Tigris trial of Polymyxin B Hemoadsorption in adults with endotoxic septic shock have been published in The Lancet Respiratory Medicine, confirming statistically robust survi...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Spectral Medical Pushes Back PMX-20R FDA Filing to Add 12-Month Mortality Data
Negative
Feb 26, 2026
Spectral Medical has delayed the timing of its Premarket Approval submission to the U.S. Food and Drug Administration for its PMX-20R hemoadsorption device to treat endotoxic septic shock, now targeting around late April to mid-May 2026 instead of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.